Showing 1 to 2 of 2 results


Moderna Stock Plummets 80% on Reduced COVID-19 Vaccine Sales
Moderna's stock price has fallen over 80% in the last year due to an 83% decrease in revenue from its COVID-19 vaccine, dropping from $18.9 billion in 2022 to $3.1 billion over the last twelve months, and projected to reach $2.1 billion in 2025; this is primarily because of reduced demand as the pan...
Moderna Stock Plummets 80% on Reduced COVID-19 Vaccine Sales
Moderna's stock price has fallen over 80% in the last year due to an 83% decrease in revenue from its COVID-19 vaccine, dropping from $18.9 billion in 2022 to $3.1 billion over the last twelve months, and projected to reach $2.1 billion in 2025; this is primarily because of reduced demand as the pan...
Progress
56% Bias Score

Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...

Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales
Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...
Progress
40% Bias Score
Showing 1 to 2 of 2 results